Journo leaders in the UK warn on old regulations for new healthcare AI

The Financial Times of London is calling for caution—along with standardized and modernized regulation—around AI in healthcare.

In a brief editorial published online June 21, the influential newspaper’s editorial board acknowledges several worthwhile innovations AI is bringing to Britain’s healthcare system. However, the team warns, more oversight is needed lest the technology “prove more of a liability than an asset.”

“There are clear advantages to tireless automated assistants and researchers capable of sorting through vast piles of data,” they write. “Yet there is a danger that the new technology falls into a regulatory grey area. The lack of a single bar risks companies applying various standards to products which directly affect the public.”

Read the whole thing:

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Mark Isenberg, executive vice president of Zotec Partners, discusses key developments that will reshape the specialty this year. 

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.